An aqueous oral care fluoride treatment composition, a method of providing fluoride to a patient's tooth surface, and a method of reducing the incidence of dental caries, wherein the composition includes: 0.1 wt-% to 3.0 wt-% of a crosslinked poly acid having carboxylic acid side groups; a pharmaceutically acceptable buffer; 1.0 wt-% to 2.5 wt-% of sodium fluoride; 0.025 wt-% to 1.75 wt-% of a multivalent cation salt; and at least 60 wt-% water; wherein the weight percentages are based on the total weight of the aqueous composition.

Disclosed herein are methods and compositions for reversing the effects of a sedation agent or general anesthetic agents. The methods are useful for example for assessing a patient during a surgical procedure or a patient's physiologic state during and/or after a surgical procedure. Other uses for the methods and compositions include modulating a circadian rhythm, treating cardiac arrest, hypotension and bradycardia, and preventing emergence delirium.

Disclosed herein are methods and compositions for reversing the effects of a sedation agent or general anesthetic agents. The methods are useful for example for assessing a patient during a surgical procedure or a patient's physiologic state during and/or after a surgical procedure. Other uses for the methods and compositions include modulating a circadian rhythm, treating cardiac arrest, hypotension and bradycardia, and preventing emergence delirium.

The invention relates to a chewing gum composition for use in the alleviation of xerostomia induced by radiotherapy treatment, where the chewing gum composition comprises gum base and substantially no flavour ingredients. Moreover, the invention also relates to a dosage regimen for administering the chewing gum composition for use in alleviation of xerostomia induced by radiotherapy treatment. So in one embodiment of the invention the chewing gum composition is administered to a human subject before and/or during and/or after radiotherapy treatment.

The invention relates to a chewing gum composition for use in the alleviation of xerostomia induced by radiotherapy treatment, where the chewing gum composition comprises gum base and substantially no flavour ingredients. Moreover, the invention also relates to a dosage regimen for administering the chewing gum composition for use in alleviation of xerostomia induced by radiotherapy treatment. So in one embodiment of the invention the chewing gum composition is administered to a human subject before and/or during and/or after radiotherapy treatment.

An aqueous oral care fluoride treatment composition, a method of providing fluoride to a patient's tooth surface, and a method of reducing the incidence of dental caries, wherein the composition includes: 0.5 wt-% to 4.8 wt-% of a water-soluble cationic N-containing polymer, a pharmaceutically acceptable buffer, 1.0 wt-% to 2.5 wt-% of sodium fluoride; and at least 60 wt-% water, wherein the weight percentages are based on the total weight of the aqueous composition.

The present invention relates to improved phosphopeptide stabilised amorphous calcium phosphate and/or amorphous calcium fluoride phosphate complexes and compositions containing those complexes. Methods of making the complexes of the invention and of treatment dental hypersensitivity are also provided. In one embodiment, the invention provides a stannous-associated phosphopeptide (PP) stabilized amorphous calcium phosphate (ACP) or amorphous calcium fluoride phosphate (ACFP) complex having a stannous ion content of equal to, or greater than, 1 mole of stannous per mole of PP but less than 4 moles of stannous per mole of PP.

The present invention relates to improved phosphopeptide stabilised amorphous calcium phosphate and/or amorphous calcium fluoride phosphate complexes and compositions containing those complexes. Methods of making the complexes of the invention and of treatment dental hypersensitivity are also provided. In one embodiment, the invention provides a stannous-associated phosphopeptide (PP) stabilized amorphous calcium phosphate (ACP) or amorphous calcium fluoride phosphate (ACFP) complex having a stannous ion content of equal to, or greater than, 1 mole of stannous per mole of PP but less than 4 moles of stannous per mole of PP.

A microcapsule composition comprising at least one polymer substantially disposed as a semi-permeable shell around an aqueous buffered solution and at least one agent, wherein the agent permeates the shell, and wherein the composition is suitable for delivery to a mammal. This invention also provides related compositions, products and methods.

A microcapsule composition comprising at least one polymer substantially disposed as a semi-permeable shell around an aqueous buffered solution and at least one agent, wherein the agent permeates the shell, and wherein the composition is suitable for delivery to a mammal. This invention also provides related compositions, products and methods.